We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




High-Tech Method for Protein Biomarker Assay Testing to Revolutionize POC Diagnosis

By LabMedica International staff writers
Posted on 23 Jun 2022

An accessible universal solution to offer rapid personalized mobile testing for infectious diseases – or diagnosis and delivery of targeted treatments for other diseases even in remote areas – has so far been out of reach. More...

Now, a speedy high-tech method of inexpensive, accurate and high-throughput protein biomarker assay testing is being touted as a much-needed development in point-of-care (PoC) testing.

Researchers at Flinders University (Adelaide, Australia) who specialize in ‘green’ vortex fluidic device (VFD) medical applications have developed a VFD that can test for infectious diseases such as flu and COVID-19 within five minutes. The new method using the revolutionary VFD can be readily scaled up to test hundreds and ‘potentially thousands’ of proteins in one assay in less than five minutes. While many costly tests can take upwards of 48-72 hours, on-the-spot tests such as this can lead to accurate diagnosis and early commencement of important drug treatments and reduction of wrong medications.

In a trial, the new method, labeled VFD-accelerated immoblot assay (VAIA), was compared and found superior to other PoC biomarker-based tests currently in use. Not only was the processing faster and accurate, it sliced up to 70% off the cost of sometimes toxic reagents. While many immunoblot assays are used to detect certain diseases, many are not highly sensitive and complex to use – even for technicians in a laboratory or clinical setting. In contrast the VAIA was found to improve conventional processing time from hours to less than five minutes, using three major immunoassay formats with purified proteins and biofluids.

“Most importantly, the data produced can be accurately read with a cell phone camera – immediately addressing the gap between development and implementation of biomarker-based precision medicine,” said Professor Gregory Weiss, senior researcher from the University of California, who is a US leader in VFD experiments and applications.

“The extreme disparity between technologically lagging and advanced settings directly impacts disease mortality and morbidity, particularly for infectious diseases,” added Dr. Xuan Luo, a Flinders University researcher.

Related Links:
Flinders University 


Gold Member
Hematology Analyzer
Medonic M32B
New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more

Microbiology

view channel
Image: Development of targeted therapeutics and diagnostics for extrapulmonary tuberculosis at University Hospital Cologne (Photo courtesy of Michael Wodak/Uniklinik Köln)

Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis

Extrapulmonary tuberculosis (EPTB) remains difficult to diagnose and treat because it spreads beyond the lungs and lacks easily accessible biomarkers. Despite TB infecting 10 million people yearly, the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.